Redi-Data, Inc. – Trademark Portfolio
Entity Type: 03
Redi-Data, Inc. owns a portfolio of 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as REDI-DATA, REDI-COUNTS, REDI-BUSINESS, REDI-CONSUMER, and REDI PHYSICIAN. Of these, 6 are registered. The portfolio spans 4 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 9 (Computers & Electronics). Headquartered in Fairfield, NJ.
107 Little Falls Road
Fairfield, NJ 07004
Showing of trademarks Trademarks
Trademark Classifications
Redi-Data, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Redi-Data, Inc. have?
Redi-Data, Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 3 abandoned, 2 cancelled.
What trademark classes does Redi-Data, Inc. file in?
Redi-Data, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 9 (Computers & Electronics), Class 38 (Telecommunications), Class 42 (Computer & Scientific). Class 35 covers advertising; business management; business administration; office functions.
What are Redi-Data, Inc.'s most well-known trademarks?
Redi-Data, Inc.'s registered trademark portfolio includes well-known marks such as REDI-DATA, REDI-COUNTS, REDI-BUSINESS, REDI-CONSUMER, and REDI PHYSICIAN. These are among 6 currently registered trademarks in the portfolio.
What is Redi-Data, Inc.'s trademark registration success rate?
Redi-Data, Inc. has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.